Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496217 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19509409 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL18954971 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL1936920 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19880310 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19502688 | 0.93 | TAS1R3 (0.46) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19502422 | 0.93 | TAS1R3 (0.46) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL25496214 | 0.92 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL23350694 | 0.92 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19491657 | 0.88 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1STING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | KDM4E 3823/4885TAS1R3 2352/4885TAS1R1 1847/4885 |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | SLC5A11, POLRMT, MAPK11 | KDM4E 3480/4885TAS1R3 3998/4885TAS1R1 3287/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | KDM4E 1268/4885TAS1R3 4231/4885TAS1R1 4165/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | KDM4E 2664/4885TAS1R3 4261/4885TAS1R1 4266/4885 |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | NSUN2, SNRPB2, RNGTT | KDM4E 1268/4885TAS1R3 4231/4885TAS1R1 4165/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | KDM4E 3200/4885TAS1R3 3654/4885TAS1R1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.